About neximmune inc - NEXI
NexImmune, Inc. is a clinical stage biotechnology company, which engages in the development of novel approach to immunotherapy designed to employ the body's own T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke on June 7, 2011 and is headquartered in Gaithersburg, MD.
NEXI At a Glance
NexImmune, Inc.
9119 Gaither Road
Gaithersburg, Maryland 20877
| Phone | 1-301-825-9810 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -32,344,393.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
NEXI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.674 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.029 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.084 |
NEXI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -5,390,732.167 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NEXI Liquidity
| Current Ratio | 1.062 |
| Quick Ratio | 1.062 |
| Cash Ratio | 0.634 |
NEXI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -125.235 |
| Return on Equity | -180.643 |
| Return on Total Capital | -903.847 |
| Return on Invested Capital | -178.521 |
NEXI Capital Structure
| Total Debt to Total Equity | 1.961 |
| Total Debt to Total Capital | 1.923 |
| Total Debt to Total Assets | 0.801 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |